Selective lysis of acute myeloid leukemia cells by CD34/CD3 bispecific antibody through the activation of γδ T-cells.
Humans
Antibodies, Bispecific
/ pharmacology
Leukemia, Myeloid, Acute
/ immunology
Antigens, CD34
/ metabolism
CD3 Complex
/ immunology
Receptors, Antigen, T-Cell, gamma-delta
/ metabolism
Lymphocyte Activation
/ immunology
Cell Line, Tumor
Cytotoxicity, Immunologic
T-Lymphocytes
/ immunology
Intraepithelial Lymphocytes
/ immunology
Acute myeloid leukemia
CD34
bispecific antibodies
cancer immunology
γδ T-cells
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2024
2024
Historique:
medline:
30
7
2024
pubmed:
30
7
2024
entrez:
30
7
2024
Statut:
epublish
Résumé
Despite the considerable progress in acute myeloid leukemia (AML) treatment, relapse after allogeneic hematopoietic stem cell transplantation (HSCT) is still frequent and associated with a poor prognosis. Relapse has been shown to be correlated with an incomplete eradication of CD34+ leukemic stem cells prior to HSCT. Previously, we have shown that a novel CD34-directed, bispecific T-cell engager (BTE) can efficiently redirect the T-cell effector function toward cancer cells, thus eliminating leukemic cells
Identifiants
pubmed: 39076247
doi: 10.1080/2162402X.2024.2379063
pii: 2379063
pmc: PMC11285226
doi:
Substances chimiques
Antibodies, Bispecific
0
Antigens, CD34
0
CD3 Complex
0
Receptors, Antigen, T-Cell, gamma-delta
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2379063Informations de copyright
© 2024 The Author(s). Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
No potential conflict of interest was reported by the author(s).